Edgewise Therapeutics

Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics

France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.

By Frank Vinluan

BioPharma, Pharma

Design Therapeutics leads way as 4 bio IPOs raise $641M for clinical research

Design Therapeutics raised $240 million in the biggest biotech IPO this week. One other rare disease drug developer went public along with two oncology biotechs as the IPO momentum continues.

By Frank Vinluan

The Hidden Administrative Tasks Draining Small Practices

Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®